Genprex Granted Patent In Singapore For Reqorsa Gene Therapy In Combination With PD-1 Antibodies Through 2037
Portfolio Pulse from Benzinga Newsdesk
Genprex has been granted a patent in Singapore for its Reqorsa gene therapy in combination with PD-1 antibodies, extending protection through 2037. This expands on previously granted patents covering the use of REQORSA with immune checkpoint inhibitors.
August 13, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genprex has been granted a patent in Singapore for its Reqorsa gene therapy in combination with PD-1 antibodies, extending protection through 2037. This expands on previously granted patents covering the use of REQORSA with immune checkpoint inhibitors.
The new patent extends the protection of Genprex's Reqorsa gene therapy, potentially enhancing its market position and future revenue streams. This is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100